Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects
Bibliographic record
Abstract
CN08-04 About one in nine women in the Western world develop cancer of the breast and at least 5% of these cases are thought to result from a hereditary predisposition to the disease. Two breast cancer susceptibility (BRCA)genes have been identified and mutations in these genes account for most families with four or more cases of breast cancer diagnosed before the age of 60. Women who inherit loss-of-function mutations in either of these genes have an up to 85% risk of breast cancer by age 70. As well as breast cancer, carriers of mutations in BRCA1 and BRCA2 are at elevated risk of cancer of the ovary, prostate and pancreas. The genes are thought to be tumour suppressor genes as the wild-type allele of the gene is observed to be lost in tumours of heterozygous carriers. Both BRCA1 and BRCA2 have significant roles in the maintenance of genome integrity via roles in the repair of DNA damage via homologous recombination. The specific DNA repair defect in BRCA-mutant cells provides opportunities for novel therapeutic approaches based on selective inhibition of functionally interacting repair pathways, in particular by inhibition of the enzyme PARP. Here I will describe recent work defining determinants of sensitivity and resistance to PARP inhibitors, as well as the application of the synthetic lethal approach to other cancer types. Selected publications Turner N, Tutt A, Ashworth A (2004) Hallmarks of 9BRCAness9 in sporadic cancers. Nat Rev Cancer 4: 814-819 Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921 Lord, C.J., Garrett, M.D. and Ashworth, A. (2006) Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin Cancer Res, 12, 4463-4468. Iorns, E., Lord, C.J., Turner, N. and Ashworth, A. (2007) Utilizing RNA interference to enhance cancer drug development. Nat Rev Drug Disc, 6, 556-568.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".